Alivus Life Sciences (ALIVUS) Fundamentals 2026 — P/E 24.8x, Revenue Analysis | SniperIQ
Alivus Life Sciences (ALIVUS) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹13,957 Crore, trading at ₹1137.15 on the BSE. This SniperIQ fundamentals page covers Alivus Life Sciences's valuation (P/E 24.8x, P/B 4.2x), profitability (net margin 22.1%), revenue (₹2,552 Crore in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Alivus Life Sciences's market cap?
Alivus Life Sciences (ALIVUS) has a market capitalization of approximately ₹13,957 Crore, trading at ₹1137.15 on the BSE. Market cap moves with the live share price.
What is Alivus Life Sciences's P/E ratio?
Alivus Life Sciences's trailing twelve-month P/E ratio is 24.8x, with a price-to-book (P/B) of 4.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Alivus Life Sciences?
Alivus Life Sciences runs a net profit margin of 22.1%, a gross margin of 47.7%, and an operating margin of 28.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Alivus Life Sciences generate?
Alivus Life Sciences reported revenue of ₹2,552 Crore for fiscal year 2025, with net income of ₹564 Crore and earnings per share (EPS) of 45.99. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Alivus Life Sciences pay a dividend?
Alivus Life Sciences offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Alivus Life Sciences financially healthy?
Alivus Life Sciences carries a debt-to-equity ratio of 0.02x and a current ratio of 5.21x, with a market beta of 0.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Alivus Life Sciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Alivus Life Sciences (ALIVUS) the key facts are: market cap ₹13,957 Crore, P/E 24.8x, revenue ₹2,552 Crore, 52-week range 830-1193.3. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Alivus Life Sciences's full fundamentals live
Get Alivus Life Sciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.